Sugi Predict

Sugi Predict / Compounds / SCHEMBL3782929

SCHEMBL3782929

SCHEMBL3782929

CC(C)(C)n1nc(O)c2c(N)ncnc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 14/20 0.58
▸ ABL1 P00519 9/20 0.58
▸ PRKD3 O94806 5/20 0.57
▸ PRKD2 Q9BZL6 5/20 0.57
▸ RIPK2 O43353 4/20 0.57
▸ FYN P06241 4/20 0.57
▸ KDR P35968 4/20 0.57
▸ CSNK1D P48730 3/20 0.57
▸ EGFR P00533 3/20 0.57
▸ PRKACA P17612 3/20 0.57
▸ CSNK1A1 P48729 3/20 0.57
▸ MAPK14 Q16539 3/20 0.57
▸ CSK P41240 3/20 0.57
▸ RET P07949 3/20 0.57
▸ KDM4E B2RXH2 2/20 0.57
▸ ALDH1A1 P00352 2/20 0.57
▸ LMNA P02545 2/20 0.57
▸ LCK P06239 2/20 0.57
▸ YES1 P07947 2/20 0.57
▸ LYN P07948 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13019650 0.83 SRC (0.64) SRCABL1PRKD3PRKD2RIPK2
SCHEMBL3788404 0.81 SRC (0.57) SRCABL1PRKD3PRKD2RIPK2
SCHEMBL15471369 0.80 SRC (0.58) SRCABL1PRKD3PRKD2RIPK2
SCHEMBL2961144 0.80 SRC (0.58) SRCABL1PRKD3PRKD2RIPK2
SCHEMBL15929311 0.80 SRC (0.61) SRCABL1PRKD3PRKD2RIPK2
SCHEMBL23055859 0.80 SRC (0.58) SRCABL1PRKD3PRKD2RIPK2
SCHEMBL22521563 0.80 KDM4E (0.63) SRCABL1PRKD3PRKD2RIPK2
SCHEMBL22369962 0.80 SRC (0.55) SRCABL1PRKD3PRKD2RIPK2
SCHEMBL3788099 0.80 SRC (0.57) SRCABL1PRKD3PRKD2RIPK2
SCHEMBL3784292 0.78 RET (0.58) SRCABL1PRKD3PRKD2RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210347780-A1 CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO Vyera Pharmaceuticals, LLC 2021-11-11 — — US disclosed
WO-2017161344-A1 COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES THE REGANTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-09-21 — — WO disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 — — US disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 — — US disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 — — US disclosed
WO-2009062118-A2 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2009-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210347780-A1 CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO CAMKK1, CAMK1, CAMKK2 SRC 408/4885ABL1 446/4885PRKD3 167/4885
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING RAB1A, COPB1, GOLT1B SRC 1332/4885ABL1 1725/4885PRKD3 1366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.